New Two-Pronged attack on tough blood cancer enters human testing
NCT ID NCT07093554
Summary
This early-stage study is testing a new two-step treatment for multiple myeloma that has come back or is not responding to other therapies. First, patients receive a drug called talquetamab to help prepare their body. Then, they receive an infusion of their own genetically modified immune cells (cilta-cel) designed to hunt and kill the cancer. The main goal is to see if this combination is safe and feasible for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.